Compare Apple Inc (AAPL) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Apple Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Apple Inc trades at $305.05 (market cap $4.50T), while Regeneron Pharmaceuticals Inc trades at $799 (market cap $83.19B). The key difference: Apple Inc is far larger — about 54.1× Regeneron Pharmaceuticals Inc's market cap, and Regeneron Pharmaceuticals Inc pays the higher dividend (0.47%). Which is the better fit depends on your goals.
| AAPL | REGN | |
|---|---|---|
Market Cap | $4.50T | $83.19B |
Volume | 100,358,844 | — |
Sector | Technology | Health |
52-Week High | $340.08 | $812.27 |
52-Week Low | $224.90 | $545.94 |
Enterprise Value | $4.52T | $77.90B |
Dividend Yield | 0.35% | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AAPL trades at $304.91, down 2.69% on the day, amid bearish technical signals but strong fundamentals. The stock shows robust profitability with a 27.62% net margin and has beaten EPS estimates in recent quarters. Analyst consensus is bullish with a $337.63 price target, though recent news highlights union tensions and potential Q3 earnings pressure from weaker iPhone sales.
Outlook remains positive due to solid cash flow and AI growth potential, but risks include retail challenges, regulatory scrutiny, and high valuation multiples. Institutional activity is mixed, with some trimming positions ahead of earnings.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apple Inc
Apple Inc. designs, manufactures, and markets personal computers and related personal computing and mobile communication devices along with a variety of related software, services, peripherals, and networking solutions. Apple sells its products worldwide through its online stores, its retail stores, its direct sales force, third-party wholesalers, and resellers.
Read more on AAPL →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
